<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00162643</url>
  </required_header>
  <id_info>
    <org_study_id>SALUD-2003-C01-123</org_study_id>
    <nct_id>NCT00162643</nct_id>
  </id_info>
  <brief_title>PI Vs. NNRTI Based Therapy for HIV Advanced Disease</brief_title>
  <official_title>Boosted PI VS. NNRTI Based Therapy as Initial Treatment for HIV-1 Infected Patients With Advanced Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Council of Science and Technology, Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto Mexicano del Seguro Social</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</source>
  <brief_summary>
    <textblock>
      Ritonavir boosted protease inhibitor based therapy will have equivalent antiviral efficacy&#xD;
      over 48 weeks compared to NNRTI based therapy in patients who are antiretroviral therapy&#xD;
      naïve and initiate therapy with CD4 counts ≤ 200/mm3.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current guidelines for initial therapy in HIV infection recommend 2 NRTIs plus either a&#xD;
      ritonavir boosted protease inhibitor or a non-nucleoside reverse transcriptase inhibitor&#xD;
      (NNRTI). Recent data suggests that the rate of response to PI based therapy may be slightly&#xD;
      compromised if the baseline CD4 count is ≤ 200/mm3 and the plasma HIV-1-RNA ≥ 100,000&#xD;
      copies/mL. This may not be equally apparent if ritonavir boosted protease inhibitors are&#xD;
      used. The effect of baseline CD4 count and HIV-1-RNA levels on the antiviral efficacy of&#xD;
      NNRTI based regimens has been less well characterized. A significant number of patients&#xD;
      currently initiate therapy at late stages of progression, typically with baseline CD4 count&#xD;
      is ≤ 200/mm3. In Mexico approximately 60% of patients who initiate therapy are within this&#xD;
      range of CD4 cell counts. Currently, the two combinations recommended as preferred are with&#xD;
      two NRTIs and either Efavirenz or Lopinavir/ritonavir, while other combinations of PIs and&#xD;
      ritonavir are considered alternative.&#xD;
&#xD;
      Comparison: The efficacy of ritonavir boosted protease inhibitor based therapy versus NNRTI&#xD;
      based therapy in patients who are antiretroviral therapy naïve and initiate therapy with a&#xD;
      CD4 count ≤ 200/mm3.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2004</start_date>
  <completion_date>December 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients who reach HIV-1-RNA ≤ 50 copies/mL at 48 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>plasma Viral Load change from baseline</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical symptoms</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 counts</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuations</measure>
  </secondary_outcome>
  <enrollment>300</enrollment>
  <condition>Acquired Immunodeficiency Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zidovudine+lamivudine+lopinavir/ritonavir</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zidovudine + lamivudine + efavirenz</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV infected individuals&#xD;
&#xD;
          -  Men or women at least 18 years old&#xD;
&#xD;
          -  CD4+ T cells ≤200/ml&#xD;
&#xD;
          -  Antiretroviral naive&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Suspected or documented active, untreated HIV 1 related opportunistic infection (OI)&#xD;
             or other condition requiring acute therapy (e.g., hepatitis C virus infection)&#xD;
&#xD;
          -  Platelet count &lt; 75,000 cells/mm3.&#xD;
&#xD;
          -  Hemoglobin &lt; 9 g/dL .&#xD;
&#xD;
          -  AST and/or ALT greater than 5 times the upper limit of normal&#xD;
&#xD;
          -  Documented or suspected active tuberculosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan G Sierra-Madero, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juan G Sierra-Madero, MD</last_name>
    <phone>5255-56559675</phone>
    <email>jsmadero@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Angelina Villasis-Keever, MD MSc</last_name>
    <phone>5255-56559675</phone>
    <email>avkeever@prodigy.net.mx</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital de Especialidades Centro Medico Nacional siglo XXI</name>
      <address>
        <city>Mexico City</city>
        <state>D.f.</state>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leticia M Perez-Saleme, MD</last_name>
      <phone>5255-56-27 69 00</phone>
      <phone_ext>21547</phone_ext>
      <email>lepesa@prodigy.net.mx</email>
    </contact>
    <investigator>
      <last_name>Leticia M Perez-Saleme, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</name>
      <address>
        <city>Mexico City</city>
        <state>DF</state>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelina Villasis-Keever, MD MSc</last_name>
      <phone>5255-56559675</phone>
      <email>avkeever@prodigy.net.mx</email>
    </contact>
    <contact_backup>
      <last_name>Luis E. Soto-Ramirez, MD</last_name>
      <phone>5255-56559675</phone>
      <email>lsoto@quetzal.innsz.mx</email>
    </contact_backup>
    <investigator>
      <last_name>Angelina Villasis-Keever, MD MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luis E Soto-Ramirez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Regional #53</name>
      <address>
        <city>Los Reyes La Paz</city>
        <state>Estado de Mexico</state>
        <zip>56400</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Mendez-Cardos, MD</last_name>
      <phone>5255-5855 4414</phone>
      <phone_ext>238</phone_ext>
      <email>kalekbuda74@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Patricia Mendez-Cardos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Regional #72</name>
      <address>
        <city>Tlalnepantla</city>
        <state>Estado de Mexico</state>
        <zip>54000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernanda Gutierrez-Escolano, MD MSc</last_name>
      <phone>5255-5565 9210</phone>
      <phone_ext>320</phone_ext>
      <email>fernandamx@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Pueblito Pizano-Gonzalez, MD</last_name>
      <phone>5255-5565 9210</phone>
      <phone_ext>320</phone_ext>
    </contact_backup>
    <investigator>
      <last_name>Fernanda Gutierrez-Escolano, MD MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pueblito Pizano-Gonzalez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Regional de Leon</name>
      <address>
        <city>Leon</city>
        <state>Guanajuato</state>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan L Mosqueda-Gomez, MD</last_name>
      <phone>5255-4771310037</phone>
      <email>luis_mosqueda@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Juan L Mosqueda-Gomez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>September 2006</verification_date>
  <study_first_submitted>September 7, 2005</study_first_submitted>
  <study_first_submitted_qc>September 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2005</study_first_posted>
  <last_update_submitted>September 13, 2006</last_update_submitted>
  <last_update_submitted_qc>September 13, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2006</last_update_posted>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Antiretroviral Therapy, Highly Active</keyword>
  <keyword>Protease Inhibitors</keyword>
  <keyword>Reverse Transcriptase Inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

